Medication is often the first-line therapy, but relief can be inadequate and temporary.

Lake Regional Urology now offers the UroLift® System, the first permanent implant to treat flow issues in men diagnosed with BPH (benign prostatic hyperplasia). The UroLift System is FDA-approved to relieve symptoms caused by an enlarged prostate, while preserving sexual function.

“The UroLift System is a safe, proven first-line alternative to surgery for men suffering from an enlarged prostate,” said Lake Regional Urologist Eric McQueary, D.O. “Lake Regional Urology is committed to providing patients with the highest quality, most effective options to address their urology needs. Importantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.”

More than 500 million aging men worldwide have an enlarged prostate. Medication is often the first-line therapy, but relief can be inadequate and temporary. Side effects of treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or ablates prostate tissue to open the blocked urethra. While this kind of surgery can be very effective in relieving symptoms, it also can leave patients with permanent side effects such as urinary incontinence and erectile dysfunction.

“Because of these potential downsides, many men delay treatment,” Dr. McQueary said. “UroLift provides another option.”

The UroLift System delivers permanent implants during a minimally-invasive procedure performed in the clinic. These implants act like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients recover from the procedure quickly, and return to their normal routines with minimal downtime.

Data from clinical trials showed that patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow and sustained sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.

“If you think you are a candidate for UroLift treatment, talk to your doctor,” Dr. McQueary said. “He or she can help you understand the potential risks and benefits.”